MSK Research Highlights, October 13, 2022
New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute suggests a therapeutic strategy to overcome resistance to PRMT5 inhibition in lymphoma; finds safety and clinical benefit using an engineered adenovirus in combination with immunotherapy against PD-1-resistant melanoma; and uncovers a new type of immune cell that plays a key role in establishing a healthy gut microbiome.